skip to the content

Clinical Trials

Respiratory Papillomatosis - Celebrex Study

A Multicentered Randomized Study of Celebrex (Celecoxib) in Patients with Recurrent Respiratory Papillomatosis

Protocol ID

03.02.131

Protocol Description

This research study that will test the efficacy of Celebrex (celecoxib) in patients with moderate to severe recurrent respiratory papillomatosis as compared to surgical removal.   Celebrex is FDA approved and most commonly used to relieve the signs and symptoms of osteoarthritis and rheumatoid arthritis in adults. Recently, Celebrex received FDA approval to relieve the signs and symptoms of juvenile rheumatoid arthritis in children.  Experimental evidence suggests that an enzyme called COX-2 contributes to tumor formation and Celebrex works by blocking that enzyme. In the laboratory setting, we have also found that Celebrex reduces the activity of the virus that causes your disease and the growth of papilloma cells.  The use of Celebrex for treatment of recurrent respiratory papillomatosis is experimental (not approved by the United States Food and Drug Administration (FDA). 

Eligibility Criteria

Patients with moderate to severe recurrent respiratory papillomatosis

Primary Investigator(s)

  • Bettie Steinberg, PhD

Contact Information

Ginny Mullooly, RN
(718) 470-7011
mullooly@lij.edu

Last Update

April 2, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Infectious Diseases:
top
top